Bial announced that the Phase 2b ACTIVATE study of BIA 28-6156 did not meet its primary, nor the key secondary efficacy endpoints.
Phase 4 ELEVATE-PD interim data from the entire study population (n=214) continue to show clinically meaningful, consistent benefits of CREXONT across all prior treatment groupsSubstantial increases ...
Zacks Investment Research on MSN
Denali stock dips as Biogen-partnered Parkinson's disease study fails
Shares of Denali Therapeutics, Inc. DNLI were down 8% in after-market trading on May 21, after the company and partner Biogen BIIB announced disappointing top-line results from a mid-stage study ...
NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with ...
TAR-200 for Bacillus Calmette-Guérin–Unresponsive High-Risk Non–Muscle-Invasive Bladder Cancer: Results From the Phase IIb SunRISe-1 Study Of 140 patients enrolled, 48.6% had stage IVM1b/c/d disease, ...
A major new study forecasts that Parkinson’s disease will affect over 25 million people globally by 2050, urging immediate action to tackle the growing neurological health crisis. Study: Projections ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results